Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomics analysis of skeletal muscle in humans with heart failure

ABSTRACT: Transcriptomics analysis of skeletal muscle in humans with heart failure

PROVIDER: PRJEB35460 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3671310.fastq.gz	Fastqsanger.gz
	ERR3671311.fastq.gz	Fastqsanger.gz
	ERR3671312.fastq.gz	Fastqsanger.gz
	ERR3671313.fastq.gz	Fastqsanger.gz
	ERR3671314.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

Transcriptomics analysis of skeletal muscle in humans with heart failure

Project description:Heart failure is a multisystem syndrome caused by structural and functional defects in multiple tissues. The study aims to identify differentially regulated genes in skeletal muscle of heart failure patients. Here, we obtained biopsies from the pectoralis major muscle and performed RNA sequencing to profile the gene expression patterns from six heart failure patients and three healthy controls.

2020-09-07 | E-MTAB-8531 | biostudies-arrayexpress

Contribution of skeletal muscle-specific microRNA to insulin resistance in heart failure

Project description:Exercise intolerance (EI) and insulin resistance (IR) are hallmarks of heart failure (HF). Abnormalities in skeletal muscle metabolism, where glucose is a major energy source, have been identified in HF and may be a link between EI and IR but the underlying mechanisms are poorly understood.

2022-06-30 | GSE207121 | GEO

Sex differences in skeletal muscle pathology in patients with heart failure and reduced ejection

Project description:Females with heart failure and reduced ejection fraction (HFrEF) have greater physical limitations and a lower quality of life compared to males, however, the role of non-cardiac mechanisms remains poorly resolved. We hypothesized that differences in skeletal muscle pathology between males and females with HFrEF may explain clinical heterogeneity. In this study, we performed an unbiased RNA sequencing of 5 male controls, 5 female controls, 6 male HFrEF patients, and 5 female HFrEF patients.

2024-07-12 | E-MTAB-14110 | biostudies-arrayexpress

Effects of enhanced external counterpulsation on skeletal muscle gene expression in patients with severe heart failure

Project description:Male patients (n=6, mean age 62 years) with NYHA III-IV and an left ventricular ejection fraction of <35% despite pharmacological therapy received 35 hours of enhanced external counterpulsation (EECP) over a period of 7 weeks. Before and after treatment, lateral vastus muscle biopsies were obtained and skeletal muscle gene expression was evaluated using the Affymetrix HuGene 1.0 platform. Skeletal muscle gene expression before and after treatment with enhanced external counterpulsation for 7 weeks in 6 male patients with severe heart failure

2016-06-01 | E-GEOD-72807 | biostudies-arrayexpress

Sex modulates genome regulatory system in heart failure in humans

Project description:Sex modulates genome regulatory system in heart failure in humans

| PRJNA877032 | ENA

Skeletal muscle derived Musclin protects the heart during pathological overload

Project description:Cachexia is associated with poor prognosis in patients with chronic heart failure. The underlying mechanisms of cachexia triggered heart failure progression, however, are not well understood. Here, we investigated whether the dysregulation of myokine expression from wasting skeletal muscle and impaired inter-organ crosstalk during advanced heart failure might contribute to progression of the disease. RNA sequencing analysis from wasting skeletal muscles of mice with cardiac cachexia during long-term pressure overload revealed a strongly reduced expression of Ostn. Ostn encodes for the skeletal muscle derived myokine Musclin, which had been previously implicated in the enhancement of natriuretic peptide (NP) signaling. Using newly developed skeletal muscle specific, inducible Ostn knock-out mice, we demonstrated that reduced skeletal muscle Musclin levels exaggerated cardiac dysfunction and myocardial fibrosis compared to littermate control mice after TAC. Restoration of Musclin deficiency during cardiac cachexia via AAV6-mediated skeletal muscle specific Musclin overexpression, in turn, attenuated left ventricular dysfunction and myocardial fibrosis. Mechanistically, we found that Musclin enhanced CNP/NPR2/cGMP signaling in cardiomyocytes, which led to improved contractility by inhibition of the cAMP degrading phosphodiesterase (PDE)3 and augmented cAMP/protein kinase A signaling. In addition, Musclin directly acted on cardiac fibroblasts to inhibit their activation. Together, our study indicates the therapeutic potential of targeting interorgan cross-talk during heart failure, for example by counteracting the impaired secretion of the Musclin from wasting skeletal muscle.

2021-11-02 | GSE129205 | GEO

Contribution of skeletal muscle-specific microRNA to insulin resistance in heart failure

Project description:Contribution of skeletal muscle-specific microRNA to insulin resistance in heart failure

| PRJNA853756 | ENA

Left ventricular samples from humans with ischemic heart failure and non-failing controls

Project description:LCMS files from tryptic digests of ~1-4 mg piece of heart ventricular tissue from human with ischemic heart failure and non-failing controls. Specimen number correspond to .raw files as follows: Ischemic Heart failure - 54687.1; HF_1_phos.raw 53148.1; HF_2_phos.raw 53589.2; HF_3_phos.raw 54146.1; HF_4_phos.raw 52935.1; HF_5_phos.raw Non-failing - 52941.1; NHF_1_phos.raw 52777.1; NHF_2_phos.raw 53019.2; NHF_3_phos.raw 53058.1; NHF_4_phos.raw 52621.1; NHF_5_phos.raw

2022-12-07 | MSV000090858 | MassIVE

INO80 and heart failure.

Project description:INO80 and heart failure.

| PRJNA1002579 | ENA

Sex differences in skeletal muscle pathology in patients with heart failure and reduced ejection

Project description:Sex differences in skeletal muscle pathology in patients with heart failure and reduced ejection

| PRJEB76056 | ENA